Zúñiga-Guajardo S, Aldrete VJ, Alexanderson REG, Arechavaleta GMR, García GE, García HPA, González GG, Mendoza ZV, Violante ORM

Language: Spanish
References: 41
Page: 141-159
PDF size: 696.57 Kb.

ABSTRACT

Type 2 diabetes mellitus (DM2) is a woldwide pandemic and currently represents one of the main causes of morbidity and mortality for health care systems. Associated complications are frequent, progressive, severe and costly. Although currently available treatments have diverse mechanisms of action, none of them modify the physiopathology of the disease, so the pancreatic beta cell degeneration progresses inexorably and some of them can be associated with several adverse effects including hypoglycemia, weight gain, gastrointestinal effects and peripheral edema. New medications based on effects on incretins favorably reduce glycosylated hemoglobin (A1c), induce weight loss and have a low risk of hypoglycemia. Liraglutide is the first type 1 glucagon-like peptide (GLP-1) analogue approved for once daily administration. The LEAD (Liraglutide Effect and Action in Diabetes) study program results have demonstrated its favorable effect on A1c, with sustained weight loss and a low risk of hypoglycemia, evidenci ng a favorable metabolic profile for effects on lipids and systolic blood pressure. Also, its use can be initiated since the earliest stages of the disease and combined with any antidiabetic regimen. The following article thoroughly reviews the LEAD program and the most current evidence available for this innovative treatment option for DM2.

REFERENCES

1. King H, Aubert RE, Herman WH. Global Burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-1431

2. AACE/ACE Consensus Statement. American Association of Clinical Endocrinologists/ American College of Endocrinology. Consensus Panel on Type 2 diabetes mellitus an algorithm for glycemic control. Endocrine Pract 2009;15:541-559

3. Aguilar-Salinas CA, Velázquez MO, Gómez-Pérez FJ, et al. Characteristic of patients with type 2 diabetes in México: Results from large population-based nationwide survey. Diabetes Care 2003;26:2021-2026

4. Arredondo A, Zuñiga A. Economic consequences of epidemiological changes in diabetes in middle-income countries: the Mexican case. Diabetes Care 2004;27:104-109

5. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53

6. Turner RC. The U.K. Prospective Diabetes Study. A review. Diabetes Care 1998;21 (Suppl.3): 35-38.

7. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for Type 2 diabetes mellitus. Ann Intern Med 2007;147:386-399

8. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203

9. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443

10. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in type 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-1147.

11. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes.Diabetologia 1986;29:46-52

12. Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose stimulated insulin secretion: effects on β-cell sensitivity in Type 2 and nondiabetic subjects. Diabetes 2003;52:380-386

13. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;2131-2157

14. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in Type 2 diabetes: a parallelgroup study. Lancet 2002;359:824830

15. Madsbad S, Krarup T, Deacon CF, Holst JJ. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care 2008;11:491-499

16. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficay: a meta-regresion analysis. Diabetes Care 2006;29:2137-2139

17. Agerso H, Vicini P. Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. Eur J Pharm Sci 2003;19:142-150

18. Damhold B, Golor G, Wierich W, Pedersen P, Ekblom M, Zdravkovic M, An open label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol 2006;46:635-641

19. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagonlike peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002;87:1239-1246

20. Zdravkovic M, Ekblom M, Brondsted L, Vouis J, Lennerns H, Malm-Erjefalt M. The effect of liraglutide on the absorption pharmacokinetics of concomitant oral drugs with different solubility and permeability properties in healthy subjects. Diabetologia 2008;51:S355

21. Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, et al. Liraglutide, a oncedaily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26(3):268-78.

22. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes (LEAD-2). Diabetes Care 2009;32(1):84-90

23. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373(9662):473-81.

24. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009(7);32:1224-30.

25. Rusell-Jones D, Vaag A, Scmitz O, et al. Liraglutine vs insulin glargine and placebo combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU):a randomised controlled trial. Diabetologia 2009; 52: 2046-2055.

26. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374:39-47.

27. Madsbad S. Liraglutide effect and action in diabetes (LEAD™) trial. Expert Rev Endocrinol Metab 2009;(4): 119-29.

28. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447-56.

29. McGill JB. insights from the liraglutide clinical development program-the liraglutide effect and action in diabetes (LEAD) studies. Postgrad Med 2009;121(3):16-25.

30. Noel RA, Braun DK, Patterson R, Bloomgren G. Increased risk of acute pancreatitis observed in patients with type 2 diabetes. Pancreas 2008; 37(4): 487.

31. Rodbard HW, Jel*linger PS, Davidson JA, et al. Glycemic control algorithm. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15(6): 513-655.

32. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008;31(1):173-5.

33. Rosas-Guzmán J, Lyra R. Documento de posición de Sociedades de Diabetes y Endocrinología de America Latina sobre el Tratamiento de Diabetes Tipo 2. Revista ALAD 2009, XVII (2): 69-76.

34. Canadian Diabetes Association. Clinical Practice Guidelines for the Prevention and Manegement of Diabetes in Canada. Canadian Journal of Diabetes 2008 (32); Suppl 1.

35. Rolin B, Larsen MO, Gotfresen CF, Deacon CF,Carr RD, Wilken M, et al. The long-acting GLP-1,derivative NN2211ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002;283:E7 45-52

36. Nicolucci A, Rossi M. Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes. Acta Biomed 2008; 79: 184-191.

37. Astrup A, Rössner S, Van Gaal L, et al. And on behalf of the NN8022-1807 Study Group, Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebocontrolled study. Lancet 374 (2009), pp. 1606–1616 ,

38. Fonseca V, Falahati A, Zychma Madsbad S, Plutzy J. A metaanalysis of six clinical trials demostrates that the once daily human GLP-1 analogue liraglutide reduces systolic blood pressure (p761). Presented at the 45 th Annual Meeting of the European Association for the Study of Diabetes, Vienna, 2009 29 th September-2nd

39. Joffe D. Liraglutide a once daily human glucagon like peptide-1 analogue for type 2 diabetes mellitus. Am J Health Syst Pharm 2010 Aug 15;67(16):1326-36.